In short
- Semaglutide mimics the gut hormone GLP-1: it increases insulin release depending on blood glucose, slows stomach emptying and dampens appetite.
- In the EU there are three products: Ozempic and Rybelsus for type 2 diabetes, Wegovy for weight management.
- In the STEP 1 trial, adults with obesity lost on average 14.9% of their body weight over 68 weeks (placebo: 2.4%).
- Drug class
- GLP-1 receptor agonist
- Given
- weekly (pen) or daily (tablet)
- Half-life
- approx. 1 week
- Prescription
- required
What is semaglutide?
Semaglutide is a man-made counterpart of the body's own gut hormone GLP-1 (glucagon-like peptide 1). The natural hormone is released after eating and broken down within minutes. Semaglutide is modified to bind to the blood protein albumin and to be broken down slowly – according to the product information its half-life is about one week. That is why one pen injection per week is enough.
Products and approval in the EU
| Product | Form | Approved for (EU) |
|---|---|---|
| Ozempic | pen, once weekly | type 2 diabetes |
| Wegovy | pen, once weekly | weight management (BMI 30+, or 27+ with a related condition) |
| Rybelsus | tablet, daily | type 2 diabetes |
Ozempic and Wegovy contain the same active ingredient but differ in approval, pens and strengths. All three products require a prescription; the dose and how it is increased are decided by the treating doctor. The term titration explains why this is done step by step.
How semaglutide works
- Pancreas: more insulin and less glucagon – but only when blood glucose is raised. That is why hypoglycaemia is rare when it is used on its own.
- Stomach: emptying slows down, so you stay full for longer.
- Brain: in appetite centres, semaglutide dampens hunger and food cravings.
The first lesson of the GLP-1 basics course explains this in more detail.
What the major trials show
In the STEP 1 trial, 1,961 adults with overweight or obesity but without diabetes received semaglutide 2.4 mg or placebo for 68 weeks, each alongside diet and exercise counselling. Body weight fell by 14.9% on average, compared with 2.4% on placebo.
The SELECT trial studied 17,604 people with cardiovascular disease and overweight but without diabetes. Major cardiovascular events (heart attack, stroke, cardiovascular death) occurred in 6.5% on semaglutide and 8.0% on placebo – a 20% lower relative risk.
Common side effects and warnings
According to the product information, gastrointestinal symptoms are among the most common side effects: nausea, vomiting, diarrhoea, constipation and abdominal pain, especially while the dose is being increased. The product information also lists, among others:
- a higher risk of gallstones,
- warnings about pancreatitis (persistent severe abdominal pain needs medical attention),
- hypoglycaemia in combination with insulin or sulfonylureas,
- possible worsening of kidney function with dehydration from vomiting or diarrhoea.
Tell your doctor or anaesthetist about the treatment before surgery or sedation, because the stomach empties more slowly.
Doses, injection sites and supply at a glance
Document your prescribed therapy: reminders, injection-site rotation, vials and history – privately synced.
Frequently asked questions
Is semaglutide the same as Ozempic?
Semaglutide is the active ingredient, Ozempic one of three brand names. Wegovy and Rybelsus contain the same ingredient but are approved for other uses or as a tablet.
How quickly does semaglutide work?
Appetite often drops within the first weeks. The full effect on weight and HbA1c develops over months – in STEP 1, weight fell over 68 weeks.
What happens when you stop semaglutide?
Studies show that part of the lost weight returns after stopping. Ongoing medical guidance and habits matter.
Sources
- EMA: Ozempic (semaglutide) – product information
- EMA: Wegovy (semaglutide) – product information
- EMA: Rybelsus (semaglutide) – product information
- Wilding JPH et al.: Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med 2021
- Lincoff AM et al.: Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). N Engl J Med 2023
- Drucker DJ: Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab 2018
Written by the BeBetr editorial team with AI assistance; facts checked against the sources listed (as of Nov 21, 2026). This content is for information only and does not replace medical advice, diagnosis or treatment.
BeBetr